Featured Publications
Distinct neural networks predict cocaine versus cannabis treatment outcomes
Lichenstein S, Kohler R, Ye F, Potenza M, Kiluk B, Yip S. Distinct neural networks predict cocaine versus cannabis treatment outcomes. Molecular Psychiatry 2023, 28: 3365-3372. PMID: 37308679, PMCID: PMC10713861, DOI: 10.1038/s41380-023-02120-0.Peer-Reviewed Original ResearchConceptsConnectome-based predictive modelingCognitive behavior therapyCognitive behavioral therapySubstance use disordersCannabis abstinenceNeural mechanismsBehavior therapyDistinct neural networksComputer-based trainingCannabis use disorderFMRI scanningNeural predictorsStudy 1Study 2Treatment outcomesContingency managementPrior workComparison subjectsNetwork strengthUse disordersNovel treatment targetsAbstinenceIndependent samplesCocaine abstinenceTreatment responders
2020
Is monetary reward processing altered in drug-naïve youth with a behavioral addiction? Findings from internet gaming disorder
Yao YW, Liu L, Worhunsky PD, Lichenstein S, Ma SS, Zhu L, Shi XH, Yang S, Zhang JT, Yip SW. Is monetary reward processing altered in drug-naïve youth with a behavioral addiction? Findings from internet gaming disorder. NeuroImage Clinical 2020, 26: 102202. PMID: 32045732, PMCID: PMC7013339, DOI: 10.1016/j.nicl.2020.102202.Peer-Reviewed Original ResearchConceptsMonetary reward processingInternet gaming disorderReward processingBehavioral addictionsSubstance use disordersNeural responsesGaming disorderMonetary incentive delay taskCurrent fMRI studyDrug-naïve young adultsNon-drug rewardsAltered reward processingIncentive delay taskDrug-naïve youthUse disordersDelay taskProcessing alterationsCaudate activityFMRI studyDrugs of abuseTrait featuresNeural activityNeural featuresOutcome stageSubstance exposure
2019
Dissociable neural substrates of opioid and cocaine use identified via connectome-based modelling
Lichenstein SD, Scheinost D, Potenza MN, Carroll KM, Yip SW. Dissociable neural substrates of opioid and cocaine use identified via connectome-based modelling. Molecular Psychiatry 2019, 26: 4383-4393. PMID: 31719641, PMCID: PMC7214212, DOI: 10.1038/s41380-019-0586-y.Peer-Reviewed Original ResearchConceptsBrain statesDissociable neural substratesMultiple brain statesSubstance use outcomesHealthy comparison subjectsWhole-brain approachFMRI scanningFrontoparietal networkNeural substratesSubstance use treatmentNeural mechanismsDifferent brain statesFurther clinical relevanceDefault modeFMRI dataSubject replicationTreatment approachesReduced connectivityUse outcomesComparison subjectsNetwork strengthUse disordersSensory networksTreatment respondersSensory connectivityAnhedonia as a Key Clinical Feature in the Maintenance and Treatment of Opioid Use Disorder
Kiluk BD, Yip SW, DeVito EE, Carroll KM, Sofuoglu M. Anhedonia as a Key Clinical Feature in the Maintenance and Treatment of Opioid Use Disorder. Clinical Psychological Science 2019, 7: 1190-1206. PMID: 32042509, PMCID: PMC7009780, DOI: 10.1177/2167702619855659.Peer-Reviewed Original ResearchOpioid use disorderClinical featuresUse disordersHigher anhedonia scoresKey clinical featuresRate of participantsAnhedonia scoresOpioid-dependent sampleOpioid cravingOpioid useTreatment adherenceHealthy controlsSignificant anhedoniaPharmacological interventionsAssessment of anhedoniaMajority of studiesPotential targetAnhedoniaTreatmentTime courseDisordersSignificant knowledge gapsScoresPotential implicationsCritical needDouble‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use
Carroll KM, DeVito EE, Yip SW, Nich C, Sofuoglu M. Double‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use. American Journal On Addictions 2019, 28: 238-245. PMID: 31165574, PMCID: PMC9078084, DOI: 10.1111/ajad.12904.Peer-Reviewed Original ResearchConceptsMethadone-maintained individualsOpioid useSecondary analysisMultiple drugsConcurrent cocaine dependenceTrial of galantaminePlacebo-controlled trialDouble-blind placeboIllicit opioid useRandomized clinical trialsCocaine use disorderGalantamine's effectFuture trialsClinical trialsUrine specimenUrine specimensUse disordersOpioidsCholinesterase inhibitorsMaintenance settingCocaine useCocaine dependencePlaceboConcurrent useGalantamineConnectome-Based Prediction of Cocaine Abstinence
Yip SW, Scheinost D, Potenza MN, Carroll KM. Connectome-Based Prediction of Cocaine Abstinence. American Journal Of Psychiatry 2019, 176: 156-164. PMID: 30606049, PMCID: PMC6481181, DOI: 10.1176/appi.ajp.2018.17101147.Peer-Reviewed Original ResearchMeSH KeywordsAdultBehavior TherapyBrainCholinesterase InhibitorsCocaine-Related DisordersCognitionConnectomeExecutive FunctionFemaleFunctional NeuroimagingGalantamineHumansIndividualityMachine LearningMagnetic Resonance ImagingMaleMiddle AgedNeural PathwaysOpiate Substitution TreatmentOpioid-Related DisordersPrognosisRewardTreatment OutcomeConceptsConnectome-based predictive modelingCocaine use disorderUse disordersBrain-based predictorsLarge-scale neural networksFunctional MRI dataCocaine abstinenceExecutive controlReward responsivenessIndividual differencesBaseline cocaine usePosttreatment assessmentConnectivity strengthHeterogeneous sampleAbstinenceIndependent samplesNovel interventionsCanonical networksSpecific behaviorsCocaine useSignificant correspondenceDisordersTreatment outcomesNetwork strengthMRI data
2018
Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder
Carroll KM, Nich C, Frankforter TL, Yip SW, Kiluk BD, DeVito EE, Sofuoglu M. Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder. Drug And Alcohol Dependence 2018, 192: 264-270. PMID: 30300800, PMCID: PMC6203294, DOI: 10.1016/j.drugalcdep.2018.08.019.Peer-Reviewed Original ResearchConceptsOpioid use disorderOral naltrexoneUse disordersAffective symptomsVoucher-based contingency managementDysphoric symptomsAffective distressOral naltrexone treatmentMultiple baseline characteristicsBaseline characteristicsNaltrexone treatmentHigh riskNaltrexoneSomatic symptomsSymptomsContingency managementTreatmentHigh rateDistressSubstantial evidenceTrialsTheoretical benefitsDisordersAffective discomfortParticipantsThe Cholinergic System as a Treatment Target for Opioid Use Disorder
Jensen KP, DeVito EE, Yip S, Carroll KM, Sofuoglu M. The Cholinergic System as a Treatment Target for Opioid Use Disorder. CNS Drugs 2018, 32: 981-996. PMID: 30259415, PMCID: PMC6314885, DOI: 10.1007/s40263-018-0572-y.Peer-Reviewed Original ResearchConceptsCholinergic systemUse disordersTreatment targetsOpioid use disorder epidemicCentral nervous system functionTreatment of OUDEffects of acetylcholineOpioid use disorderTobacco use disorderNervous system functionOpioid medicationsDegrade acetylcholineCurrent treatmentOpioid overdosesPreclinical studiesMedicationsAcetylcholineCholinesterase inhibitorsAlzheimer's diseaseNew treatmentsAccidental deathGlobal healthTreatmentOUDDisease
2012
Reduced Subjective Response to Acute Ethanol Administration Among Young Men with a Broad Bipolar Phenotype
Yip SW, Doherty J, Wakeley J, Saunders K, Tzagarakis C, de Wit H, Goodwin GM, Rogers RD. Reduced Subjective Response to Acute Ethanol Administration Among Young Men with a Broad Bipolar Phenotype. Neuropsychopharmacology 2012, 37: 1808-1815. PMID: 22491350, PMCID: PMC3376329, DOI: 10.1038/npp.2012.45.Peer-Reviewed Original ResearchConceptsAlcohol use disorderWeekly alcohol intakeBipolar disorderAlcohol intakeSubjective responsesAcute ethanol administrationLifetime prevalence ratesDevelopment of AUDPlacebo administrationAcute alcoholEthanol administrationHealthy controlsSedative responsePharmacokinetic effectsEtiological factorsPrevalence ratesUse disordersAlcohol misusePharmacokinetic responseFamilial riskAlcohol responsesYoung malesIntoxication effectsBipolar phenotypeYoung men